Peripherally administered cisplatin activates a parvocellular neuronal subtype expressing arginine vasopressin and enhanced green fluorescent protein in the paraventricular nucleus of a transgenic rat.
Animals
Antineoplastic Agents
/ administration & dosage
Arginine Vasopressin
/ genetics
Cisplatin
/ administration & dosage
Corticosterone
/ blood
Corticotropin-Releasing Hormone
/ genetics
Genes, Reporter
Green Fluorescent Proteins
/ genetics
Injections, Intraperitoneal
Male
Neurons
/ drug effects
Paraventricular Hypothalamic Nucleus
/ drug effects
Proto-Oncogene Proteins c-fos
/ metabolism
Rats, Transgenic
Rats, Wistar
Recombinant Fusion Proteins
/ metabolism
Up-Regulation
Arginine vasopressin
Cisplatin
Enhanced green fluorescent protein
Fos B
Journal
The journal of physiological sciences : JPS
ISSN: 1880-6562
Titre abrégé: J Physiol Sci
Pays: Japan
ID NLM: 101262417
Informations de publication
Date de publication:
10 Jul 2020
10 Jul 2020
Historique:
received:
22
03
2020
accepted:
06
07
2020
entrez:
12
7
2020
pubmed:
12
7
2020
medline:
8
7
2021
Statut:
epublish
Résumé
Cisplatin is one of the most potent anti-cancer drugs, though several side effects can induce stress responses such as activation of the hypothalamic-pituitary adrenal (HPA) axis. Arginine vasopressin (AVP) and corticotrophin-releasing hormone (CRH) expressed in the parvocellular division of the paraventricular nucleus (pPVN) play an important role in the stress-induced activation of the HPA axis. We aimed to evaluate whether intraperitoneal (i.p.) administration of cisplatin could activate parvocellular neurons in the pPVN, using a transgenic rat model that expresses the fusion gene of AVP and enhanced green fluorescent protein (eGFP). Along with the induction of FosB, a marker of neuronal activation, i.p. administration of cisplatin significantly increased eGFP fluorescent intensities in the pPVN. In situ hybridization histochemistry revealed that AVP-eGFP and CRH mRNAs in the pPVN were increased significantly in cisplatin-treated rats. These results suggest that cisplatin administration increases neuronal activation and upregulates AVP and CRH expression in the pPVN.
Identifiants
pubmed: 32650712
doi: 10.1186/s12576-020-00764-z
pii: 10.1186/s12576-020-00764-z
pmc: PMC10717609
doi:
Substances chimiques
Antineoplastic Agents
0
Fosb protein, rat
0
Proto-Oncogene Proteins c-fos
0
Recombinant Fusion Proteins
0
enhanced green fluorescent protein
0
Arginine Vasopressin
113-79-1
Green Fluorescent Proteins
147336-22-9
Corticotropin-Releasing Hormone
9015-71-8
Cisplatin
Q20Q21Q62J
Corticosterone
W980KJ009P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Subventions
Organisme : Grant-in-Aid for Scientific Research
ID : 17H04027
Organisme : Grant-in-Aid for Scientific Research on Innovative Areas
ID : 15H05940
Références
Psychoneuroendocrinology. 2009 Feb;34(2):259-272
pubmed: 18951722
J Neuroendocrinol. 2009 Mar;21(3):183-90
pubmed: 19207829
J Physiol Sci. 2019 May;69(3):531-541
pubmed: 30937882
Brain Res Mol Brain Res. 2001 May 20;90(1):39-47
pubmed: 11376854
J Neurosci. 2009 Oct 21;29(42):13182-9
pubmed: 19846706
J Neuroendocrinol. 2005 Apr;17(4):227-37
pubmed: 15842234
Cancer Chemother Pharmacol. 2006 Sep;58(3):326-33
pubmed: 16435157
Neuroscience. 2000;100(3):549-56
pubmed: 11098118
Proc Natl Acad Sci U S A. 1984 Mar;81(6):1883-7
pubmed: 6369332
Cancers (Basel). 2011 Mar 15;3(1):1351-71
pubmed: 24212665
Nature. 2006 Sep 21;443(7109):289-95
pubmed: 16988703
Psychophysiology. 2002 Jul;39(4):491-5
pubmed: 12212641
Oncologist. 2012;17(6):756-65
pubmed: 22618570
Jpn J Clin Oncol. 1989 Mar;19(1):40-4
pubmed: 2921817
Peptides. 2013 Aug;46:13-9
pubmed: 23684922
Neurobiol Learn Mem. 2015 Sep;123:43-9
pubmed: 25982942
Biochem Biophys Res Commun. 2017 Aug 26;490(3):794-799
pubmed: 28645611
J Neuroendocrinol. 2000 Mar;12(3):255-62
pubmed: 10718921
J Ginseng Res. 2019 Oct;43(4):499-507
pubmed: 31695559
Chem Biol. 2013 Nov 21;20(11):1323-8
pubmed: 24183971
Endocrinology. 2005 Jan;146(1):406-13
pubmed: 15375027
Neurosci Lett. 2004 Apr 1;358(3):201-4
pubmed: 15039116
Exp Physiol. 2000 Mar;85 Spec No:19S-26S
pubmed: 10795903
Dialogues Clin Neurosci. 2006;8(4):383-95
pubmed: 17290797
J Neuroendocrinol. 2007 Apr;19(4):285-92
pubmed: 17355318
Brain Res. 2011 Nov 18;1424:1-8
pubmed: 22005685
Prog Neurobiol. 1993 May;40(5):573-629
pubmed: 8484004
Eur J Pharmacol. 2000 Sep 29;405(1-3):225-34
pubmed: 11033330
Nat Rev Cancer. 2007 Aug;7(8):573-84
pubmed: 17625587
Neurosci Res. 2019 Jun;143:53-60
pubmed: 29879461
Cancer Chemother Pharmacol. 2011 Mar;67(3):667-86
pubmed: 20509026
Obstet Gynecol Sci. 2017 Jan;60(1):115-117
pubmed: 28217682
Regul Pept. 2000 Dec 22;96(1-2):23-9
pubmed: 11102648
Pharmacol Biochem Behav. 2006 Jan;83(1):9-20
pubmed: 16443263
Mol Metab. 2014 Jan 08;3(2):209-15
pubmed: 24634830
J Physiol Sci. 2018 Jul;68(4):471-482
pubmed: 28616820
Ther Clin Risk Manag. 2009 Apr;5(2):375-84
pubmed: 19536319
J Psychiatr Res. 2007 Jan-Feb;41(1-2):131-43
pubmed: 16455105
Endocrinology. 1983 Sep;113(3):939-42
pubmed: 6307672
J Neuroendocrinol. 2009 Oct;21(10):822-31
pubmed: 19686449